SUBTOTAL (3) (\$)

0.00

•	\				•							
•	•						. •	-				1636
٠.												700
											PTO/S	
								11 S D-	stoot on	Appro	ived for use through 7/31/2006. ON irk Office; U.S. DEPARTMENT OF	IB 0651-0032
EID		ne Paperw	ork Red	fuction Act of 1995, no	persons are requi	red to re	espond t				on unless it displays a valid OMB co	
AE 10		== :	TD	ANICAL	TTAI					Com	plete if Known	
do.	TO HO XX	==	IK	ANSMI	IIAL	L	Applic	cation I	Numb	er	09/921,143-Conf. #6449	<u> </u>
0.0	8	f	or	FY 200	Λ	L	Filing	Date			August 3, 2001	
G	<i>美</i>	_		Patent fees are subject to	_		First I	Named	Inver	itor	Timothy A. Coleman	
Pr.			72003, F	-aleni rees are subject to	annual revision.	—	Exam	iner Na	ıme		C. X. Qian	
WIENT & TR	A	pplicant c	taims si	mall entity status. See	37 CFR 1.27		Art Ur	nit			1636	
		MOUNT	r OF P	AYMENT (\$)	0.00		Attom	ey Doc	ket No).	PF112P6	
	ME	THOD C)F PA	YMENT (check all tha					FFF	CALCU	LATION (continued)	
			Credit	Money -		2 4	ODITI	20141			27411014 (continued)	
	Chec		Card	Order U	her None	3. A	DDITIO	UNAL	rees			
	χ Depo	osit Accou	nt:				F-42-	C!!	F-414.			
	Deposit Account			08-3425		Fee	Entity Fee	Fee	Entity Fee	-	For Description	
	Number					Code	(\$)	Code	(\$)		Fee Description	Fee Paid
	Deposit Account	Huma	n Ger	nome Sciences, I	nc.	1051	130	2051	65	Surcharge	e – late filing fee or oath	
	Name			o: (check all that apply)		1052	50	2052	25		e – late provisional filing fee or cover	
		pe fee(s) ind			y overpayments	1053	130	1053	120	sheet.	ah a-salfaasias	
										_	sh specification	<u> </u>
	X Charg	e any addit	ional fee	e(s) or any underpayment	of fee(s)	1812	2,520	1812	•	-	request for ex parte reexamination	
	Charge	je fee(s) ind	licated b	elow, except for the filing	g fee	1804	920*	1804	920*	Examiner	g publication of SIR prior to action	
	to the above	e-identifie	d depos	it account.		1805	1,840*	1805	1,840*	Requestin Examiner	g publication of SIR after	
			FEE C	ALCULATION		1251	110	2251	55		for reply within first month	
	1. BASIC		FEE			1252	420	2252	210	Extension	for reply within second month	
	Large Entity	٠.	Entity Fee	Fee Description	Fee Paid	1253	950	2253	475	Extension	for reply within third month	
!	Code (\$)		(\$)	ree Description	ree raid	1254	1,480	2254	740		for reply within fourth month	
	1001 770		385	Utility filing fee		1255	2,010	2255			for reply within fifth month	L
	1002 340 1003 530		170 265	Design filing fee		1401	330 330	2401 2402		Notice of		
	1003 330		385	Plant filing fee Reissue filing fee		1403	290	2403		-	ief in support of an appeal or oral hearing	
	1005 160		80	Provisional filing fee		1451	1,510	1451		-	institute a public use proceeding	
			CHIDT	OTAL (4) (%)	0.00	1452	110	2452	55		revive – unavoidable	
	6		3061	OTAL (1) (\$)	0.00	1453	1,330	2453	665	Petition to	revive - unintentional	
	2. EXTRA	A CLAIM	FEES	FOR UTILITY AN	D REISSUE	1501	1,330	2501	665	Utility issu	e fee (or reissue)	
]			Extra Fee from Claims below	Fee Paid	1502	480	2502	240	Design iss	sue fee	
	Total Claims		-** =	×	=	1503	640	2503	320	Plant issu	e fee	
	Independent Claims	•	-** =	×	=	1460	130	1460	130	Petitions t	o the Commissioner	
	Multiple Dep	endent			=	1807	50	1807	50	Processin	g fee under 37 CFR 1.17(q)	
	Large Entity					1806	180	1806	180		on of Information Disclosure Stmt	
	Fee Fee Code (\$)		Fee (\$)	Fee Descript	ion	8021	40	8021	40		each patent assignment per imes number of properties)]
1	1202 18			laims in excess of 20		1809	770	2809	385	Filing a su	bmission after final rejection	
	1201 86			ndependent claims in ex						(37 CFR 1 For each a	.129(a)) additional invention to be	
	1203 290			Aultiple dependent claim	-	1810	770	2810	385	examined	(37CFR 1.129(b))	⊢
	1204 86	2204	43 **	 Reissue independent of over original patent 	aaims	1801	770	2801	385	•	or Continued Examination (RCE) or expedited examination	\vdash
	1205 18	2205	9 **	* Reissue daims in exce	ess of 20	1802	900	1802	900		n application	

SUBMITTED BY			(Complete	(if applicable))
Name (Print/Type) Nelissa J. Pytel	Registration No. (Attorney/Agent)	41,512	Telephone	(301) 610-5764
Signature			Date	August 10, 2004
	8			

Other fee (specify)

*Reduced by Basic Filing Fee Paid

0.00

1205 18 2205

** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater, For Reissues, see above



In re Patent Application of:

Timothy A. Coleman

Docket No.: PF112P6

Application No.: 09/921,143

Confirmation No.: 6449

Filed: August 3, 2001

Art Unit: 1636

For: Vascular Endothelial Growth Factor 2

Examiner: C. X. Qian

SIXTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references GU-GW listed on the attached Form PTO/SB/08. Copies of the references are enclosed.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

The undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Sixth Supplemental Information Disclosure Statement was first

cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Sixth Supplemental Information Disclosure Statement. In particular, the listed references were cited in a European Supplementary Search Report (reference GW) mailed July 14, 2004, in connection with a corresponding international application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: August 10, 2004

Respectfully submitted,

Melissa J. Pytel

Registration No.: 41,512

HUMAN GENOME SCIENCES, INC.

Intellectual Property Dept. 14200 Shady Grove Road Rockville, Maryland 20850

(301) 610-5764

MMW/MJP/ba



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
rk Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known					
Application Number	09/921,143-Conf. #6449				
Filing Date	August 3, 2001				
First Named Inventor	Timothy A. Coleman				
Art Unit	1636				
Examiner Name	C. X. Qian				
Attorney Docket Number	PF112P6				

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵			
						1			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²					
	GU	SCHRATZBERGER et al., "Reversal of experimental diabetic neuropathy by VEGF gene transfer," <i>J. Clin. Invest.</i> , 107(9):1083-1092 (May 2001)						
	GV	VALE et al., "Randomized, Single-Blind, Placebo-Controlled Pilot Study of Catheter-Based Myocardial Gene Transfer for Therapeutic Angiogenesis Using Left Ventricular Electromechanical Mapping in Patients with Chronic Myocardial Ischemia," <i>Circulation</i> , 103:17:2138-2143 (May 1, 2001)						
	GW	European Supplementary Search Report, Application No. EP 01 96 3814, mailed July 14, 2004						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.